Articles
-
PBMs Are Inflating the Cost of Generic Drugs. They Must Be Reined In
Anti-competitive practices and a lack of transparency in the generic drug market allow pharmacy benefit managers to profit off patients and payers.
Categorized in -
Surprise Billing Dispute Resolution Outcomes in Texas Anchored to Median In-Network Allowed Amount
Analysis of cases that went through dispute resolution found the final allowed were largely anchored to the established.
-
California Has a Child Care Crisis. How Finding It – and Paying for It – Can Be a Nightmare
Child care providers, many already struggling before COVID, have been hit hard over the past two years. Plummeting demand for child care, increased cleaning and supply costs, virus safety measures and capacity restrictions created a perfect storm of stressors, said providers and experts familiar with the child care field.
Categorized in -
It’s Time to Let Pharmacists Prescribe COVID-Fighting Pills Like Paxlovid
To reduce hospitalization and death, pharmacists should have the same prescribing abilities as doctors for COVID anti-viral drugs Paxlovid and Lagevrio, USC School of Pharmacy
Dean Vassilios Papadopoulos writes in a new MarketWatch op-ed.Categorized in -
Interdisciplinary Hub Fosters Innovative Solutions for Improving Diversity in Clinical Trials
USC has received $5.8 million from Gates Ventures and the American Heart Association to launch a lab aimed at diversifying clinical trials.
Categorized in -
Schaeffer White Paper Highlights Failures in Generic Drug Market That Cost Patients
A new USC Schaeffer Center paper highlights tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, that are costing patients, employers and the government billions for what should be inexpensive medicines.
Categorized in -
Electronic ‘Nudges’ May Improve Safety in Opioid Prescribing Among California Doctors, Study Finds
Researchers observed a 23% drop in opioid prescriptions and a 27% increase in prescriptions for naloxone.
Categorized in -
Comments to the Federal Trade Commission on Pharmacy Benefit Managers
Researchers at the USC Schaeffer Center have been studying the pharmaceutical distribution system since 2016; these comments about PBMs draw on that body of research.
Categorized in -
I Wrongly Expected COVID to Fade Last Summer — Here’s What to Expect This Time
After believing the pandemic would be under control by Memorial Day 2021, Schaeffer Center expert Geoffrey Joyce writes why he believes COVID is nowhere near under control.
Categorized in -
Patients Deserve Immediate Access to FDA-Approved Innovations — Not Bureaucratic Restrictions
Nonresident Senior Fellow Joe Grogan argues that the FDA approval process is slowing down drug innovation.
Categorized in